포도막염 치료제 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측 - 치료 유형별, 질환 유형별, 원인별, 유통 채널별, 지역별, 경쟁별(2020-2030년)

Global Uveitis Drugs Market was valued at USD 705.30 million in 2024 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 7.20% through 2030F. Uveitis refers to a group of inflammatory eye conditions affecting the uvea, the eye's middle layer, which includes the iris, ciliary body, and choroid. If left untreated, uveitis can lead to serious vision impairment or even blindness. The condition may be caused by infections, autoimmune disorders, trauma, or may be idiopathic. Key symptoms include eye pain, redness, blurred vision, light sensitivity, and floaters. With the global aging population on the rise and age-related eye disorders becoming more prevalent, demand for effective uveitis treatments is increasing. Advances in therapeutic formulations, coupled with heightened awareness and improved diagnostic capabilities, are further supporting market expansion. According to the World Health Organization, the population aged 60 and over is expected to grow from 900 million in 2015 to 2 billion by 2050, increasing the burden of ocular diseases such as uveitis and driving the need for effective drug therapies.

Key Market Drivers

Advancements in Treatment Options

Innovative treatment modalities have significantly enhanced uveitis management in recent years. Biologics, such as adalimumab and infliximab, offer targeted therapy by modulating the immune response responsible for inflammation. Sustained-release corticosteroid implants, including dexamethasone-based options, have improved patient compliance by reducing the frequency of administration. Intravitreal injections and advanced topical formulations have gained popularity for delivering drugs directly to the affected area while minimizing systemic side effects. In March 2025, ANI Pharmaceuticals received FDA approval for an expanded indication of ILUVIEN (fluocinolone acetonide intravitreal implant) for treating chronic non-infectious uveitis of the posterior segment (NIU-PS). This move reinforces the shift toward longer-lasting, targeted therapies in uveitis treatment. These developments underscore the growing availability of effective, patient-friendly options that are helping reshape the treatment landscape for this potentially sight-threatening condition.

Key Market Challenges

High Cost of Treatment

The cost burden associated with uveitis treatment continues to be a key constraint, especially in resource-limited settings. Advanced drugs such as biologics and intravitreal implants can be expensive, often exceeding affordability thresholds for uninsured or underinsured patients. Chronic disease management requires continuous medication, regular monitoring, and specialist consultations, all of which drive long-term healthcare expenditures. In many cases, limited access to eye care professionals and diagnostic facilities compounds these challenges, particularly in rural or underserved regions. High treatment costs may result in poor adherence or delayed treatment, thereby increasing the risk of complications and irreversible vision loss. Healthcare systems also face economic strain, with the rising prevalence of uveitis increasing demand for cost-intensive care. These barriers emphasize the urgent need for affordable treatment options, including the introduction of generics and biosimilars, to improve accessibility and reduce the financial burden on patients and providers alike.

Key Market Trends

Patient-Centric Approaches

A notable trend in the uveitis drugs market is the shift toward personalized, patient-centered care. Healthcare providers are tailoring treatment strategies based on disease subtype, severity, patient health status, and individual preferences. Shared decision-making between clinicians and patients fosters better adherence and outcomes. Enhanced patient education initiatives focus on raising awareness about uveitis symptoms, treatment importance, and disease monitoring. This approach is supported by the implementation of simplified treatment regimens and reminder systems to boost adherence. Emphasis is also placed on improving quality of life through comprehensive management plans that address the physical, psychological, and social effects of the disease. Access to educational resources and patient advocacy networks is helping individuals navigate the complexities of long-term disease management, creating a more engaged and informed patient base. These strategies reflect a broader healthcare trend focused on empowering patients and optimizing long-term outcomes.

Key Market Players

• Allergan Inc.
• Bausch & Lomb Incorporated
• Santen Pharmaceutical Co. Ltd
• AbbVie Inc.
• Novartis AG
• Eyegate Pharmaceuticals Inc.
• Regeneron Pharmaceuticals
• Eyepoint Pharmaceuticals Inc.
• Alimera Sciences Inc.

Report Scope:

In this report, the Global Uveitis Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Uveitis Drugs Market, By Treatment Type:

• Analgesics
• Antibiotics
• Antifungal
• Antivirals
• Corticosteroids
• Cycloplegic Agents
• Immunosuppressant
• Monoclonal Antibodies

Uveitis Drugs Market, By Disease Type:

• Anterior Uveitis
• Intermediate Uveitis
• Panuveitis
• Posterior Uveitis

Uveitis Drugs Market, By Cause:

• Infectious
• Noninfectious

Uveitis Drugs Market, By Distribution Channel:

• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies

Uveitis Drugs Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
• Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Uveitis Drugs Market.

Available Customizations:

Global Uveitis Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Uveitis Drugs Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Treatment Type (Analgesics, Antibiotics, Antifungal, Antivirals, Corticosteroids, Cycloplegic Agents, Immunosuppressant, Monoclonal Antibodies)
  • 5.2.2. By Disease Type (Anterior Uveitis, Intermediate Uveitis, Panuveitis, Posterior Uveitis)
  • 5.2.3. By Cause (Infectious, Noninfectious)
  • 5.2.4. By Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies)
  • 5.2.5. By Region
  • 5.2.6. By Company (2024)
• 5.3. Market Map

6. Asia Pacific Uveitis Drugs Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Treatment Type
  • 6.2.2. By Disease Type
  • 6.2.3. By Cause
  • 6.2.4. By Distribution Channel
  • 6.2.5. By Country
• 6.3. Asia Pacific: Country Analysis
  • 6.3.1. China Uveitis Drugs Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Treatment Type
      • 6.3.1.2.2. By Disease Type
      • 6.3.1.2.3. By Cause
      • 6.3.1.2.4. By Distribution Channel
  • 6.3.2. India Uveitis Drugs Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Treatment Type
      • 6.3.2.2.2. By Disease Type
      • 6.3.2.2.3. By Cause
      • 6.3.2.2.4. By Distribution Channel
  • 6.3.3. Australia Uveitis Drugs Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Treatment Type
      • 6.3.3.2.2. By Disease Type
      • 6.3.3.2.3. By Cause
      • 6.3.3.2.4. By Distribution Channel
  • 6.3.4. Japan Uveitis Drugs Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Treatment Type
      • 6.3.4.2.2. By Disease Type
      • 6.3.4.2.3. By Cause
      • 6.3.4.2.4. By Distribution Channel
  • 6.3.5. South Korea Uveitis Drugs Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Treatment Type
      • 6.3.5.2.2. By Disease Type
      • 6.3.5.2.3. By Cause
      • 6.3.5.2.4. By Distribution Channel

7. Europe Uveitis Drugs Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Treatment Type
  • 7.2.2. By Disease Type
  • 7.2.3. By Cause
  • 7.2.4. By Distribution Channel
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Uveitis Drugs Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Treatment Type
      • 7.3.1.2.2. By Disease Type
      • 7.3.1.2.3. By Cause
      • 7.3.1.2.4. By Distribution Channel
  • 7.3.2. Germany Uveitis Drugs Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Treatment Type
      • 7.3.2.2.2. By Disease Type
      • 7.3.2.2.3. By Cause
      • 7.3.2.2.4. By Distribution Channel
  • 7.3.3. Spain Uveitis Drugs Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Treatment Type
      • 7.3.3.2.2. By Disease Type
      • 7.3.3.2.3. By Cause
      • 7.3.3.2.4. By Distribution Channel
  • 7.3.4. Italy Uveitis Drugs Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Treatment Type
      • 7.3.4.2.2. By Disease Type
      • 7.3.4.2.3. By Cause
      • 7.3.4.2.4. By Distribution Channel
  • 7.3.5. United Kingdom Uveitis Drugs Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Treatment Type
      • 7.3.5.2.2. By Disease Type
      • 7.3.5.2.3. By Cause
      • 7.3.5.2.4. By Distribution Channel

8. North America Uveitis Drugs Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Treatment Type
  • 8.2.2. By Disease Type
  • 8.2.3. By Cause
  • 8.2.4. By Distribution Channel
  • 8.2.5. By Country
• 8.3. North America: Country Analysis
  • 8.3.1. United States Uveitis Drugs Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Treatment Type
      • 8.3.1.2.2. By Disease Type
      • 8.3.1.2.3. By Cause
      • 8.3.1.2.4. By Distribution Channel
  • 8.3.2. Mexico Uveitis Drugs Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Treatment Type
      • 8.3.2.2.2. By Disease Type
      • 8.3.2.2.3. By Cause
      • 8.3.2.2.4. By Distribution Channel
  • 8.3.3. Canada Uveitis Drugs Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Treatment Type
      • 8.3.3.2.2. By Disease Type
      • 8.3.3.2.3. By Cause
      • 8.3.3.2.4. By Distribution Channel

9. South America Uveitis Drugs Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Treatment Type
  • 9.2.2. By Disease Type
  • 9.2.3. By Cause
  • 9.2.4. By Distribution Channel
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Uveitis Drugs Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Treatment Type
      • 9.3.1.2.2. By Disease Type
      • 9.3.1.2.3. By Cause
      • 9.3.1.2.4. By Distribution Channel
  • 9.3.2. Argentina Uveitis Drugs Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Treatment Type
      • 9.3.2.2.2. By Disease Type
      • 9.3.2.2.3. By Cause
      • 9.3.2.2.4. By Distribution Channel
  • 9.3.3. Colombia Uveitis Drugs Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Treatment Type
      • 9.3.3.2.2. By Disease Type
      • 9.3.3.2.3. By Cause
      • 9.3.3.2.4. By Distribution Channel

10. Middle East and Africa Uveitis Drugs Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Treatment Type
  • 10.2.2. By Disease Type
  • 10.2.3. By Cause
  • 10.2.4. By Distribution Channel
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Uveitis Drugs Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Treatment Type
      • 10.3.1.2.2. By Disease Type
      • 10.3.1.2.3. By Cause
      • 10.3.1.2.4. By Distribution Channel
  • 10.3.2. Saudi Arabia Uveitis Drugs Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Treatment Type
      • 10.3.2.2.2. By Disease Type
      • 10.3.2.2.3. By Cause
      • 10.3.2.2.4. By Distribution Channel
  • 10.3.3. UAE Uveitis Drugs Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Treatment Type
      • 10.3.3.2.2. By Disease Type
      • 10.3.3.2.3. By Cause
      • 10.3.3.2.4. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Uveitis Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

• 16.1. Allergan Inc
  • 16.1.1. Business Overview
  • 16.1.2. Company Snapshot
  • 16.1.3. Products & Services
  • 16.1.4. Financials (In case of listed companies)
  • 16.1.5. Recent Developments
  • 16.1.6. SWOT Analysis
• 16.2. Bausch & Lomb Incorporated
  • 16.2.1. Business Overview
  • 16.2.2. Company Snapshot
  • 16.2.3. Products & Services
  • 16.2.4. Financials (In case of listed companies)
  • 16.2.5. Recent Developments
  • 16.2.6. SWOT Analysis
• 16.3. Santen Pharmaceutical Co Ltd.
  • 16.3.1. Business Overview
  • 16.3.2. Company Snapshot
  • 16.3.3. Products & Services
  • 16.3.4. Financials (In case of listed companies)
  • 16.3.5. Recent Developments
  • 16.3.6. SWOT Analysis
• 16.4. AbbVie Inc.
  • 16.4.1. Business Overview
  • 16.4.2. Company Snapshot
  • 16.4.3. Products & Services
  • 16.4.4. Financials (In case of listed companies)
  • 16.4.5. Recent Developments
  • 16.4.6. SWOT Analysis
• 16.5. Novartis AG
  • 16.5.1. Business Overview
  • 16.5.2. Company Snapshot
  • 16.5.3. Products & Services
  • 16.5.4. Financials (In case of listed companies)
  • 16.5.5. Recent Developments
  • 16.5.6. SWOT Analysis
• 16.6. Eyegate Pharmaceuticals; Inc.
  • 16.6.1. Business Overview
  • 16.6.2. Company Snapshot
  • 16.6.3. Products & Services
  • 16.6.4. Financials (In case of listed companies)
  • 16.6.5. Recent Developments
  • 16.6.6. SWOT Analysis
• 16.7. Regeneron Pharmaceuticals
  • 16.7.1. Business Overview
  • 16.7.2. Company Snapshot
  • 16.7.3. Products & Services
  • 16.7.4. Financials (In case of listed companies)
  • 16.7.5. Recent Developments
  • 16.7.6. SWOT Analysis
• 16.8. Eyepoint pharmaceuticals Inc.
  • 16.8.1. Business Overview
  • 16.8.2. Company Snapshot
  • 16.8.3. Products & Services
  • 16.8.4. Financials (In case of listed companies)
  • 16.8.5. Recent Developments
  • 16.8.6. SWOT Analysis
• 16.9. Alimera Sciences Inc.
  • 16.9.1. Business Overview
  • 16.9.2. Company Snapshot
  • 16.9.3. Products & Services
  • 16.9.4. Financials (In case of listed companies)
  • 16.9.5. Recent Developments
  • 16.9.6. SWOT Analysis

17. Strategic Recommendations

18. About Us & Disclaimer